Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Total Current Liabilities (2020 - 2025)

Ovid Therapeutics' Total Current Liabilities history spans 6 years, with the latest figure at $8.3 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 21.23% year-over-year to $8.3 million; the TTM value through Dec 2025 reached $8.3 million, down 21.23%, while the annual FY2025 figure was $8.3 million, 21.23% down from the prior year.
  • Total Current Liabilities reached $8.3 million in Q4 2025 per OVID's latest filing, up from $6.8 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $16.3 million in Q1 2021 to a low of $6.7 million in Q1 2023.
  • Average Total Current Liabilities over 5 years is $10.3 million, with a median of $10.1 million recorded in 2021.
  • Peak YoY movement for Total Current Liabilities: crashed 52.75% in 2022, then surged 64.1% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $14.8 million in 2021, then plummeted by 52.75% to $7.0 million in 2022, then soared by 64.1% to $11.5 million in 2023, then dropped by 8.29% to $10.5 million in 2024, then fell by 21.23% to $8.3 million in 2025.
  • Per Business Quant, the three most recent readings for OVID's Total Current Liabilities are $8.3 million (Q4 2025), $6.8 million (Q3 2025), and $8.9 million (Q2 2025).